27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Dermata Therapeutics Inc (NASDAQ:DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. DMT410 showed improvements in pore size, luminosity, brightness, and overall aesthetic appearance.
- The duration of the treatment effect lasted approximately three months.
- The Company did say that upper facial lines, a measurement of the visible improvement of a patient's forehead, lateral canthal, and glabellar lines, did not show clinically meaningful improvement.
- Dermata said that minimal effect on the upper facial lines was expected as it did not expect OnabotuliniumtoxinA to penetrate the muscle.
- DMT410 was generally safe and well-tolerated with no adverse events reported, no withdrawals due to treatment-related adverse events, and no potential distant spread of toxin reported.
- Related Link: Why Are Dermata Therapeutics Shares Trading Higher Today?
- Price Action: DRMA shares are down 29.4% at $3.35 during the market session on the last check Friday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!